Division of Breast Imaging, Department of Radiology (W.T.R., C.H.N., A.V.N.), and Division of Nuclear Medicine, Department of Radiology (R.K.J.B.), University of Michigan Health System, 1500 E Medical Center Dr, Ann Arbor, MI 48109.
Radiol Imaging Cancer. 2020 Mar 20;2(2):e190037. doi: 10.1148/rycan.2020190037. eCollection 2020 Mar.
Nuclear medicine studies are often performed in patients with breast cancer; however, incidental radiotracer uptake in the breasts can be observed in patients with nonbreast malignancies. Benign and malignant lesions can be identified on planar, SPECT, and PET scans. This review will outline the molecular and radiographic imaging appearance of benign and malignant breast lesions on sestamibi scans, bone scans, radioiodine studies, as well as PET studies using fluorine 18 (F) fluorodeoxyglucose, gallium 68 (Ga) tetraazacyclododecane tetraacetic acid octreotate (or DOTATATE), Ga prostate-specific membrane antigen, and F-fluciclovine radiotracers. Recognizing these lesions at molecular and anatomic imaging is important to ensure accurate diagnosis and appropriate management. Breast, Mammography, Molecular Imaging, PET/CT, Radionuclide Studies, SPECT/CT © RSNA, 2020.
核医学研究通常在乳腺癌患者中进行；然而，非乳腺癌恶性肿瘤患者也可观察到偶然的放射性示踪剂摄取。在平面、SPECT 和 PET 扫描上可识别良性和恶性病变。本综述将概述锝 99m 甲氧基异丁基异腈（ sestamibi ）扫描、骨扫描、放射性碘研究以及使用氟 18（F）氟脱氧葡萄糖、镓 68（Ga）四氮杂环十二烷四乙酸奥曲肽（或 DOTATATE）、Ga 前列腺特异性膜抗原和 F-氟替莫韦放射性示踪剂的良性和恶性乳腺病变的分子和放射性成像表现。在分子和解剖成像中识别这些病变对于确保准确诊断和适当治疗很重要。乳腺，乳房 X 线摄影术，分子成像，PET/CT，放射性核素研究，SPECT/CT ©RSNA，2020。
